Abstract
Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2459-2461 |
| Number of pages | 3 |
| Journal | Cancer |
| Volume | 64 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1989 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. / Chambers, Setsuko K; Chopyk, R. L.; Chambers, J. T.; Schwartz, P. E.; Duffy, T. P.
In: Cancer, Vol. 64, No. 12, 1989, p. 2459-2461.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer
AU - Chambers, Setsuko K
AU - Chopyk, R. L.
AU - Chambers, J. T.
AU - Schwartz, P. E.
AU - Duffy, T. P.
PY - 1989
Y1 - 1989
N2 - Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.
AB - Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.
UR - http://www.scopus.com/inward/record.url?scp=0024827183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024827183&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T
DO - 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T
M3 - Article
VL - 64
SP - 2459
EP - 2461
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 12
ER -